[Toloxatone and depression].
One hundred and one depressed inpatients were treated by the authors with a second-generation antidepressive original molecule: Toloxatone, a specific and reversible MAO A inhibitor. Upon admission, all 101 patients with depressive illness did not score higher than 20 on Hamilton's Scale, and did not score lower than 4 on Fischer, Fernández Labriola and Rodríguez Casanova's Endogeneity Test. Biological profiles (Phenyl-ethylamine, NA, and MHPG) were available on 57 subjects. At the beginning of the experiment: (a) No subject was taking antidepressives, (b) Patients' age averaged 46; (c) The 6-week experiment was a double-blind vs. placebo type. Daily toloxatone dose was standardized in a 400 mg intake. Significant modifications were detected in 51 subjects. Among the 59 subjects that were administered active substance, 37 achieved either "excellent" or "good" outcomes. Biological markers pointed out a profile of patients with a better response to Toloxatone: Namely, patients with a lower noradrenergic activity. Anxiety-free depression as well as inhibited depressions are a psychiatrist's choice for administering Toloxatone.
Fernández Labriola
R
R
Centro de Investigaciones Edmundo Fischer (CIEF), Buenos Aires, Argentina.
Caetano Esquivel
G
G
Alvarez
M
M
Servidio
M
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D003863:Depression / Q000188:drug therapy*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010080:Oxazoles / Q000627:therapeutic use*; D023303:Oxazolidinones; D011569:Psychiatric Status Rating Scales; D011594:Psychometrics
D010080:Oxazoles; D023303:Oxazolidinones; C010798:toloxatone
Toloxatona y depresión.